



FIGURE 1



2/31


FIGURE 2

A




Lateral to midline injection

B




Midline injection

FIGURE 3



4/31

FIGURE 4A



A

FIGURE 4B





FIGURE 5A



6/31
FIGURE 5B




FIGURE 5C




FIGURE 6A




FIGURE 6B




FIGURE 7






FIGURE 8



9/31

FIGURE 9



10/31

FIGURE 10





FIGURE 11



12/31

FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19




Baseline:
IGA-FWS: 2
PFWS: 2

Week 4:
IGA-FWS: 0
PFWS: 0

Week 24:
IGA-FWS: 1
PFWS: 1

20/31

FIGURE 20A



Baseline:	Week 4:	Week 24:
IGA-FWS: 2	IGA-FWS: 0	IGA-FWS: 0
PFWS: 2	PFWS: 0	PFWS: 0

FIGURE 20B




FIGURE 21A




FIGURE 21B

Ex. 7 Arm 1	Ex. 7 Arm 2	Ex. 8
Pivotal: 36 Weeks	Pivotal: 36 Weeks	Open-Label, Long-term Safety: 84 Weeks
N = 303	N = 306	N = 2,051
Treatment Centers: 15*	Treatment Centers: 15**	Treatment Centers: 50**
DAXI 201	DAXI 204	DAXI Treatment Cycle 1 (36 wks) 2,380
Placebo 102	Placebo 102	DAXI Treatment Cycle 2 (36 wks) 962
		DAXI Treatment Cycle 3 (12 wks) 969
		Total Number of DAXI Treatment Cycles 3,650

Total: Nearly 2,600 patients received more than 4,200 DAXI treatments across Phase 1 – 3 GL program

22/31

FIGURE 22




FIGURE 23

	Screening ^a	Treatment	Retreatment ^b	W1	W2	W4	W8	W12	W16, 20, 24	W28, 32, 36	Total Evaluation Visit ^c Or Early Discontinuation
Procedures	Days Up to 14	Day 0		Follow-up	Follow-up	Follow-up	Follow-up	Follow-up	Follow-up	Follow-up	
Review Trial Procedures, Informed Consent and Privacy Authorization	X										
Eligibility Criteria	X	X ^d									
Demographics	X										
Mechanism(s) History	X	X ^d									
Concomitant Therapy Medication	X	X ^d	X ^e	X	X	X	X	X	X	X	X
Relevant Vital Signs (temp, pulse, RR, BP)	X	X ^{d,e}	X ^{f,g}		X						X
Physical Examination	X				X						
Urine Pregnancy Test (WCBCP only)	X	X ^d	X ^d								X ^d
Clinical Labs (hematology, chemistry, PT)	X		X ^{d,h}			X ⁱ					X ^j
Blood Sample for Antibody Testing	X				X	X		X			
Urinalysis	X		X ^d			X					X
Patient Education	X	X ^d	X ^d	X	X	X	X	X	X	X	X
Patient Knows Wound Severity (PWVS)	X	X ^d	X ^d	X	X	X	X	X	X	X	X
Global Aesthetic Improvement Scale (GAIS) (Patient and Investigator)				X	X	X	X	X	X	X	X
Injection Site Evaluation	X	X ^{k,l}	X ^{m,n}	X	X	X	X	X	X	X	X
Investigator Global Patient Writable Severity (GSA-PWS)	X	X ^o	X ^p	X	X	X	X	X	X	X	X
Cranial Nerves II-VII assessments	X	X ^{q,r}	X ^{s,t}	X	X	X	X	X	X	X	X
Evaluations of Facial Muscle Strength		X ^{q,u}	X ^{v,w}	X	X	X	X	X	X	X	X
Photographs of Treatment Area (select timing) ^y		X ^z	X ^{aa}	X	X	X	X	X	X	X	X
Photographs of Treatment Area (all centers) ^b		X ^{ab}	X ^{ac}	X ^{ad}	X ^{ae}	X ^{af}	X ^{ag}	X ^{ah}	X ^{ai}	X ^{aj}	X ^{ak}
Intentional Product Administration		X	X								
Access for Eligibility for Retreatment								X	X	X	
Adverse Events	X ^{al}	X ^{am}	X ^{an}	X	X	X	X	X	X	X	X
Distant Spread of Tumor Observed	X ^{ao}	X ^{ap,q}	X ^{ar}	X ^{as}	X ^{at}	X ^{au}	X ^{av}	X ^{aw}	X ^{ax}	X ^{ay}	X ^{az}

FIGURE 24A





FIGURE 24B



25/31

FIGURE 25A






FIGURE 25B



26/31


FIGURE 26A



Data shown include Treatment 1 for OLS Group B (i.e., De Novo + Received Placebo in SAKURA 1 or 2). Treatment 2 for both Groups A and B, and results from SAKURA 1 and 2 studies.

27/31

FIGURE 26B



28/31

FIGURE 27A




FIGURE 27B




FIGURE 28A



FIGURE 28B



30/31

FIGURE 29




FIGURE 30




FIGURE 31

Table 14.2.5.2: Onset of Treatment Effect (Observed Cases) Post-treatment (Intent-to-Treat Population)

Onset of Treatment Effect	Placebo (N=102)	Daxi 401 (N=201)
Number of Patients with Diary Evaluation of the Severity of Glabellar Lines, n	99	198
Number of Patients who Achieve Onset [a]	22	189
Median	2.9	2.0
Min, Max	1, 8	1, 10
25th, 75th Percentiles	1.0, 5.9	1.0, 4.0
Number of Patients who Do Not Achieve Onset [b]	77 (77.8%)	6 (3.1%)

Abbreviations: Daxi = DaxibotulinumtoxinA.
Percentages are based on n.
[a] Number of patients who achieve onset on at least one diary evaluation of the severity of glabellar lines within the first two weeks post treatment.
[b] Number of patients who do not achieve onset on at least one diary evaluation of the severity of glabellar lines within the first two weeks post treatment.
Intent-to-Treat: All randomized patients who received at least 1 dose of study medication.

FIGURE 32

Onset of Treatment Effect	Placebo (N=102)	Daxi 401 (N=201)
Number of Patients with Diary Evaluation of the Severity of Glabellar Lines, n	100	202
Number of Patients who Achieve Onset [a]	21	197
Median	3.0	2.0
Min, Max	1, 9	1, 10
25th, 75th Percentiles	1.0, 3.0	1.0, 3.0
Number of Patients who Do Not Achieve Onset [b]	79 (79.0%)	5 (2.5%)

Abbreviations: Daxi = DaxibotulinumtoxinA.
Percentages are based on n.
[a] Number of patients who achieve onset on at least one diary evaluation of the severity of glabellar lines within the first two weeks post treatment.
[b] Number of patients who do not achieve onset on at least one diary evaluation of the severity of glabellar lines within the first two weeks post treatment.
Intent-to-Treat: All randomized patients who received at least 1 dose of study medication.